We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLN
176
Silence Therapeutics
SLN
$564M
$52.6K 0.01%
18,643
+643
+4% +$3.14K
IOVA icon
177
Iovance Biotherapeutics
IOVA
$2.87B
$52.3K 0.01%
15,700
– –
NKTR icon
178
Nektar Therapeutics
NKTR
$2.58B
$46.1K 0.01%
4,517
– –
OKUR
179
OnKure Therapeutics
OKUR
$168M
$43K 0.01%
+10,000
New +$56.2K
OVID icon
180
Ovid Therapeutics
OVID
$491M
$36.1K 0.01%
115,867
-14,665
-11% -$9.02K
MOVE icon
181
Corvex Inc
MOVE
$358M
$35K 0.01%
2,600
– –
CYPH
182
Cypherpunk Technologies Inc
CYPH
$73.3M
$33.9K 0.01%
111,000
+5,000
+5% +$5.5K
AAM.WS
183
DELISTED
AA Mission Acquisition Corp Warrants
AAM.WS
$33.6K 0.01%
505,099
– –
CTMX icon
184
CytomX Therapeutics
CTMX
$754M
$29.9K 0.01%
47,036
-98,000
-68% -$76K
ASPCR
185
A SPAC III Acquisition Corp Right
ASPCR
$29.8K 0.01%
+215,000
New +$30.2K
XLO icon
186
Xilio Therapeutics
XLO
$60.3M
$29K 0.01%
+2,857
New +$35.9K
PEPG icon
187
PepGen
PEPG
$197M
$28.6K 0.01%
+20,352
New +$41.9K
PRQR icon
188
ProQR Therapeutics
PRQR
$265M
$27.1K 0.01%
20,394
– –
NMRA icon
189
Neumora Therapeutics
NMRA
$302M
$26.1K ﹤0.01%
26,108
-42,500
-62% -$72.8K
MREO
190
Mereo BioPharma
MREO
$47.3M
$22.5K ﹤0.01%
10,000
– –
CLRB icon
191
Cellectar Biosciences
CLRB
$20.5M
$12.7K ﹤0.01%
1,341
-18,168
-93% -$165K
RLYB icon
192
Rallybio
RLYB
$85.8M
$8.77K ﹤0.01%
1,675
– –
JVSAR
193
DELISTED
JV SPAC Acquisition Corp. Right
JVSAR
$8.4K ﹤0.01%
30,000
– –
IROHR
194
DELISTED
Iron Horse Acquisitions Corp Right
IROHR
$7.5K ﹤0.01%
25,000
– –
CNTB
195
Connect Biopharma Holdings
CNTB
$139M
$5.67K ﹤0.01%
+10,300
New +$9.54K
EMCGR
196
DELISTED
Embrace Change Acquisition Corp Rights
EMCGR
$2.37K ﹤0.01%
13,144
– –
UCFIW
197
CN Healthy Food Tech Group Warrant
UCFIW
$800 ﹤0.01%
25,000
– –
EMCGW
198
DELISTED
Embrace Change Acquisition Corp Warrants
EMCGW
$695 ﹤0.01%
18,000
– –
ABCL icon
199
AbCellera Biologics
ABCL
$2.12B
– –
-14,981
Closed -$43.9K
ABSI icon
200
Absci
ABSI
$1.51B
– –
-157,665
Closed -$413K
6 7
8
9 10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.